Navigation Links
Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
Date:10/9/2009

Third Quarter 2009 Financial Results

VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the third quarter ended September 30, 2009, on Monday November 9, 2009 at 11:00 AM ET (8:00 AM Pacific).

    Dial-in information for the earnings call on November 9, 2009 is as
    follows:
    North America (toll-free): 800.599.9829
    International: 617.847.8703
    Enter Passcode: 64385781

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the call on November 9, 2009 at approximately 8:00 AM ET (5:00 AM Pacific).

An archived replay of the call will be available until November 16, 2009.

    Replay information is as follows:
    North America (toll-free): 888.286.8010
    International: 617.801.6888
    Enter Passcode: 36157253

Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,300 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.

SOURCE Angiotech Pharmaceuticals, Inc.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and Life ... free download , digs deep into this vibrant market, speaking ... today. One area where Algeria ... homegrown pharmaceutical manufacturing base, even if the government,s ambitious target ... A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Experience to the Leader in ... Cellular Bioenergetic Profiling, N. BILLERICA, ... for real-time measurement of cellular,bioenergetics in microplates, announced today that ... company,s Board of,Directors. In this position, Keegan will apply his ...
... Cadus Corporation (OTC,Bulletin Board: KDUS) announced today financial results for ... for the second quarter of 2007 and for the same ... was $218,960, compared,to net income of $75,387 for the same ... quarter of 2007 was $0.02, compared to basic net,income per ...
... a Phase II study of R1507 ... for the Treatment of Sarcoma, ... its partner, Roche has initiated a Phase II,clinical study of R1507 ... created by Genmab under the company,s,agreement with Roche and initiation of ...
Cached Biology Technology:Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2Cadus Reports Second Quarter 2007 Results 2Cadus Reports Second Quarter 2007 Results 3Cadus Reports Second Quarter 2007 Results 4Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The ... for the biometrics industry as Acuity Market Intelligence ... biometrics may finally be open. Acuity forecasts that ... mobile devices that incorporate biometrics will drive a ... 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... announced today that they have entered into ... its proprietary photocleavable biotin reagent for the ... The biggest constraint on successful ... is achieving sufficient sensitivity. SomaLogic,s innovative SOMAmer ...
... 29, 2011) The future brightened for organic chemistry when ... attach organic molecules to pristine graphene, making the miracle material ... lab of chemist James Tour, building upon a set of ... method that turned what was a single-atom-thick sheet of carbon ...
... A team of scientists from Worcester Polytechnic Institute ... Life Sciences and Bioengineering Center, have regenerated functional muscle ... clinical therapy to treat people who suffer major muscle ... coax mature human muscle cells into a stem cell-like ...
Cached Biology News:Graphene lights up with new possibilities 2Graphene lights up with new possibilities 3Body rebuilding: Researchers regenerate muscle in mice 2Body rebuilding: Researchers regenerate muscle in mice 3
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... template is designed to allow neomycin/kanamycin selection ... FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance gene ... expression of kanamycin resistance in E.coli ... expression of neomycin resistance in mammalian cells. ...
... This depletion cocktail is tailored ... cells from suspensions of rat ... using the StemSep (or compatible ... selection system. The CD4+ T ...
Biology Products: